Table 2.
Pregnancy Groups, Hormonal Contraceptive Use, and Anthropometric Characteristics at Ages 18 to 19 Years by Race
| Characteristic | Mean (SD) |
P Value | |
|---|---|---|---|
| Black Women (n=983) | White Women (n=907) | ||
| Pregnancy group, No. (%) | |||
| Nulligravidas | 560 (57.0) | 739 (81.5) | <.001 |
| Nulliparous gravidas | 114 (11.6) | 82 (9.0) | |
| Parous | 309 (31.4) | 86 (9.5) | |
| Births in paras, No. (%) | |||
| 1 Birth | 237 (76.7) | 74 (86.0) | |
| ≥ 2 Births | 72 (23.3) | 12 (14.0) | |
| Age at first birth, No. (%), y | |||
| <16 | 61 (19.7) | 13 (14.1) | .95 |
| ≥16 | 248 (80.3) | 73 (85.9) | |
| Hormonal contraceptive use at age 18-20 y, No. (%) | |||
| Never | 503 (51.2) | 503 (55.5) | <.001 |
| Past | 163 (16.6) | 95 (10.5) | |
| Current oral | 191 (19.4) | 263 (29.0) | |
| Current Depo-Proveraa or Norplantb | 126 (12.8) | 46 (5.0) | |
| Height, cm | 163.8 (6.2) | 165.2 (6.3) | <.001 |
| Weight, kg | 72.3 (15.1) | 65.3 (20.7) | <.001 |
| Body mass indexc | 26.9 (7.4) | 23.9 (5.3) | <.001 |
| Waist circumference, cm | 79.0 (14.1) | 74.5 (11.0) | <.001 |
| Hip circumference, cm | 104.1 (13.8) | 100.3 (10.1) | <.001 |
| Waist to hip ratio | 0.76 (0.056) | 0.74 (0.050) | <.001 |
| Body fat % | 33.5 (13.6) | 28.8 (10.1) | <.001 |
| Body size, No. (%) | |||
| Obesed | 258 (26.3) | 117 (12.9) | <.001 |
| Overweighte | 221 (22.5) | 138 (15.2) | |
| Normalf | 504 (51.3) | 652 (71.9) | |
a
Medroxyprogesterone. Manufactured by Pfizer, New York, New York.
b
Levonorgestrel. Manufactured by Leiras Oy Pharmaceuticals, Turku, Finland.
c
Calculated as weight in kilograms divided by height in meters squared.
d
Body mass index of 30 or greater.
e
Body mass index 25 to 29.9.
f
Body mass index less than 25.